Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veraxa Biotech Holding AGVRXA -10.66%6 Market Cap is $250.29 Mil as of Aug. 01, 2026. GuruFocus rates VRXA with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 1,422 Biotechnology companies, Veraxa Biotech Holding AG ranks better than 63.92% on this metric.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Veraxa Biotech Holding AG's Enterprise Value for Today is $250.95 Mil.
Veraxa Biotech Holding AG (NAS:VRXA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Veraxa Biotech Holding AG Market Cap Related Terms
Veraxa Biotech Holding AG Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG Market Cap Chart
Veraxa Biotech Holding AG Annual Data
Trend
Dec23
Dec24
Dec25
Market Cap
0.00
0.00
0.00
Veraxa Biotech Holding AG Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Market Cap
0.00
0.00
0.00
0.00
0.00
VRXA vs TTRX, IRD, IFRX: Market Cap Comparison
For the Biotechnology subindustry, Veraxa Biotech Holding AG's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veraxa Biotech Holding AG Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's Market Cap distribution charts can be found below:
* The bar in red indicates where Veraxa Biotech Holding AG's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veraxa Biotech Holding AG (VRXA) has a Market Cap of $250.29 Mil as of Aug. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Veraxa Biotech Holding AG and its competitors. According to the industry distribution chart, Veraxa Biotech Holding AG ranks #513 out of 1422 companies in the Biotechnology industry, placing it in the top 36.1%.
Is Veraxa Biotech Holding AG's Market Cap too high?
Veraxa Biotech Holding AG's current Market Cap is $250.29 Mil. The Biotechnology industry median Market Cap is 109.62. Veraxa Biotech Holding AG's value of $250.29 Mil is 128.3% above this industry median. Based on the distribution chart, Veraxa Biotech Holding AG ranks #513 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Veraxa Biotech Holding AG has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's Market Cap compare to TTRX and IRD?
According to the Biotechnology industry distribution chart, Veraxa Biotech Holding AG ranks #513 out of 1422 companies for Market Cap. This puts Veraxa Biotech Holding AG in the upper half of its industry. The industry median Market Cap is 109.62. Veraxa Biotech Holding AG's value of $250.29 Mil is 128.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 109.62, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veraxa Biotech Holding AG's current Market Cap of $250.29 Mil is 128.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Veraxa Biotech Holding AG and its competitors. For the Biotechnology industry, the median Market Cap is 109.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veraxa Biotech Holding AG's current Market Cap is $250.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (VRXA) has a current Market Cap of $250.29 Mil. The current Market Cap is $250.29 Mil and 128.3% above the Biotechnology industry median of 109.62. Veraxa Biotech Holding AG's overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Veraxa Biotech Holding AG (VRXA), the current Market Cap is $250.29 Mil as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
6GF Score
Get the complete analysis for VRXA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRXA has been successfully added to your 
